Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASLAN003 in Acute Myeloid Leukemia
NCT03451084Phase 2Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of farudodstat in acute myeloid leukemia (AML), sponsored by ASLAN Pharmaceuticals. Started Jan 2018; status: completed.
02
Drugs
farudodstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03451084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451084.